Drugs that contain Ponatinib Hydrochloride

1. List of Iclusig drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114874 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Jan, 2027

(3 years from now)

US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(10 years from now)

US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(10 years from now)

US11384086 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029533 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors
Dec, 2026

(3 years from now)

US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 18, 2023

Market Authorisation Date: 14 December, 2012

Treatment: A method of treating chronic myelogenous leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; A method for treating leukemia resulting from a mutation in the ...

Dosage: TABLET;ORAL

How can I launch a generic of ICLUSIG before it's patent expiration?
More Information on Dosage

ICLUSIG family patents

40

United States

8

Australia

8

China

8

Japan

6

Canada

6

European Union

5

Mexico

4

Israel

EA

4

EA

3

Brazil

3

Spain

3

Korea, Republic of

2

Denmark

2

Slovenia

2

Hungary

2

Portugal

2

Poland

1

Hong Kong

1

Lithuania

1

Cyprus

1

Chile

1

Luxembourg

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in